Predictive factors of survival outcomes in first‐line therapy for metastatic castration‐resistant prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive factors of survival outcomes in first‐line therapy for metastatic castration‐resistant prostate cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF UROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-22
DOI
10.1111/iju.14702
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate
- (2019) Akiyuki Yamamoto et al. BJU INTERNATIONAL
- Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer
- (2018) Guru Sonpavde et al. BJU INTERNATIONAL
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
- (2018) Philipp Nuhn et al. EUROPEAN UROLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare
- (2016) Masaki Shiota et al. BJU INTERNATIONAL
- Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
- (2016) Masaki Shiota et al. INTERNATIONAL JOURNAL OF UROLOGY
- Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer
- (2015) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer
- (2014) M. Shiota et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started